| Species |
Human |
| Protein Construction |
GARP & Latent TGF Beta 2 Complex [His20-Leu628 (GARP) & Leu21-Ser414 (Latent TGF Beta 2)]
Accession # Q14392 (GARP) & P61812-1 (Latent TGF Beta 2) |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
70.3 kDa(GARP)&45.53 kDa(Latent TGF Beta 2) |
| Apparent Molecular Weight |
Due to enzyme lysis and glycosylation, the protein migrates to 72-77 kDa(GARP)&13 kDa&46-48 kDa(Latent TGF Beta 2) based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
GARP&Latent TGF Beta is a complex found on surface of many types of cells. In Tregs, GARP is involved in TCR-mediated activation of Latent TGF-β and thus promoting secretion and activation of TGF-β. Integrin αvβ8 on the surface of immune cells and other cells recognizes RGD in LAP, resulting in the release of mature TGF-β from the TGF-β&GARP complex. |
| Synonyms |
Garpin; GARP; LRRC32; D11S833E; GARP&Latent TGF B; GARP&TGF B; Cetermin; G-TSF; LAP; TGF-beta-2; TGF Beta 2; GARP&Latent TGF Beta 2 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
